Systematic Review of Defibrotide Studies in the Treatment of Veno-occlusive Disease/sinusoidal Obstruction Syndrome (VOD/SOS)

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2019 Feb 27

PMID 30804485

Citations 28

Authors

Paul Richardson

Saurabh Aggarwal

Ozlem Topaloglu

Kathleen F Villa

Selim Corbacioglu

Affiliations

Soon will be listed here.

Abstract

Veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome (SOS), is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT) conditioning or high-dose nontransplant chemotherapy. VOD/SOS with multi-organ dysfunction (MOD) is associated with a mortality rate of > 80%. Defibrotide (25 mg/kg/day) is approved to treat hepatic VOD/SOS with renal or pulmonary dysfunction post HSCT in the United States and to treat severe hepatic VOD/SOS in patients > 1 month of age in the European Union. A random effects model was used for pooling data from 17 systematically chosen defibrotide studies. For patients in these reports (n = 2598), and those in the subset of 10 reports of patients treated with ~ 25 mg/kg/day (n = 1691), estimated Day + 100 survival rates were 54% and 56%, respectively. Among those patients treated with ~ 25 mg/kg/day, estimated Day + 100 survival was 44% among patients with MOD and 71% in patients without MOD; survival was 41% and 70%, respectively, for the population of patients receiving any dose of defibrotide. Safety results were not pooled owing to differences in reporting methodology but were generally consistent with the known tolerability profile of defibrotide. This analysis provides the largest assessment of survival in patients treated with defibrotide for VOD/SOS with or without MOD.

Citing Articles

Burden of illness of non-hematopoietic stem cell transplant-related hepatic sinusoidal obstruction syndrome: A systematic review.

Fan L, Stewart F, Ruiz K, Devani D, Fusco N, Gill M Heliyon. 2024; 10(20):e36883.

PMID: 39640784 PMC: 11619986. DOI: 10.1016/j.heliyon.2024.e36883.

Porto-sinusoidal Vascular Disease: Classification and Clinical Relevance.

Premkumar M, Anand A J Clin Exp Hepatol. 2024; 14(5):101396.

PMID: 38601747 PMC: 11001647. DOI: 10.1016/j.jceh.2024.101396.

Constructing training set using distance between learnt graphical models of time series data on patient physiology, to predict disease scores.

Chakrabarty D, Wang K, Roy G, Bhojgaria A, Zhang C, Pavlu J PLoS One. 2023; 18(10):e0292404.

PMID: 37856497 PMC: 10586698. DOI: 10.1371/journal.pone.0292404.

Antithrombin Therapy: Current State and Future Outlook.

Rodgers G, Mahajerin A Clin Appl Thromb Hemost. 2023; 29:10760296231205279.

PMID: 37822179 PMC: 10571690. DOI: 10.1177/10760296231205279.

Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study.

Ruutu T, Peczynski C, Houhou M, Polge E, Mohty M, Kroger N Bone Marrow Transplant. 2023; 58(11):1209-1214.

PMID: 37573397 PMC: 10622315. DOI: 10.1038/s41409-023-02077-2.

References

Pescador R, Capuzzi L, Mantovani M, Fulgenzi A, Ferrero M . Defibrotide: properties and clinical use of an old/new drug. Vascul Pharmacol. 2013; 59(1-2):1-10. DOI: 10.1016/j.vph.2013.05.001. View

Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle J . Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2017; 53(2):138-145. PMC: 5803572. DOI: 10.1038/bmt.2017.161. View

Balade Martinez L, Cabezuelo M, Villamanan Bueno E, Rodriguez Martin E, Herrero Ambrosio A . Defibrotide for the treatment of severe hepatic sinusoidal obstruction syndrome: a single-centre experience. Eur J Hosp Pharm. 2019; 26(6):343-346. PMC: 6855847. DOI: 10.1136/ejhpharm-2018-001575. View

Palomo M, Diaz-Ricart M, Rovira M, Escolar G, Carreras E . Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010; 17(4):497-506. DOI: 10.1016/j.bbmt.2010.11.019. View

Benimetskaya L, Wu S, Voskresenskiy A, Echart C, Zhou J, Shin J . Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood. 2008; 112(10):4343-52. DOI: 10.1182/blood-2008-04-149682. View

Richardson P, Grupp S, Pagliuca A, Krishnan A, Ho V, Corbacioglu S . Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. Int J Hematol Oncol. 2018; 6(3):75-93. PMC: 6171967. DOI: 10.2217/ijh-2017-0015. View

Dignan F, Wynn R, Hadzic N, Karani J, Quaglia A, Pagliuca A . BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013; 163(4):444-57. DOI: 10.1111/bjh.12558. View

Corbacioglu S, Richardson P . Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation. Expert Rev Gastroenterol Hepatol. 2017; 11(10):885-898. DOI: 10.1080/17474124.2017.1370372. View

McDonald G, Hinds M, Fisher L, Schoch H, WOLFORD J, Banaji M . Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993; 118(4):255-67. DOI: 10.7326/0003-4819-118-4-199302150-00003. View

10.

Carreras E, Bertz H, Arcese W, Vernant J, Tomas J, Hagglund H . Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic.... Blood. 1998; 92(10):3599-604. View

11.

Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T . Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. Bone Marrow Transplant. 2015; 51(3):403-9. DOI: 10.1038/bmt.2015.283. View

12.

Palomo M, Mir E, Rovira M, Escolar G, Carreras E, Diaz-Ricart M . What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. Blood. 2016; 127(13):1719-27. PMC: 4817313. DOI: 10.1182/blood-2015-10-676114. View

13.

Kernan N, Grupp S, Smith A, Arai S, Triplett B, Antin J . Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Br J Haematol. 2018; 181(6):816-827. PMC: 6032999. DOI: 10.1111/bjh.15267. View

14.

Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A . Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012; 379(9823):1301-9. DOI: 10.1016/S0140-6736(11)61938-7. View

15.

Richardson P, Elias A, Krishnan A, Wheeler C, Nath R, Hoppensteadt D . Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998; 92(3):737-44. View

16.

Chopra R, Eaton J, Grassi A, Potter M, Shaw B, Salat C . Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2001; 111(4):1122-9. DOI: 10.1046/j.1365-2141.2000.02475.x. View

17.

Dietrich C, Trenker C, Fontanilla T, Gorg C, Hausmann A, Klein S . New Ultrasound Techniques Challenge the Diagnosis of Sinusoidal Obstruction Syndrome. Ultrasound Med Biol. 2018; 44(11):2171-2182. DOI: 10.1016/j.ultrasmedbio.2018.06.002. View

18.

Strouse C, Richardson P, Prentice G, Korman S, Hume R, Nejadnik B . Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2016; 22(7):1306-1312. PMC: 4914048. DOI: 10.1016/j.bbmt.2016.04.011. View

19.

Corbacioglu S, Honig M, Lahr G, Stohr S, Berry G, Friedrich W . Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant. 2006; 38(8):547-53. DOI: 10.1038/sj.bmt.1705485. View

20.

Sucak G, Aki Z, Yagci M, Yegin Z, Ozkurt Z, Haznedar R . Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience. Transplant Proc. 2007; 39(5):1558-63. DOI: 10.1016/j.transproceed.2007.01.075. View